Načítá se...
Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers
In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Landes Bioscience
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/ https://ncbi.nlm.nih.gov/pubmed/23760495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|